JNM CE/SAM (November 2020): Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents
JNM, November 2020, Volume 61, Number 11
Release Date: November 1, 2020
Expiration Date: November 30, 2023
SNMMI Members: Free
Non-Members: $69.00
Continuing Education Credit Information
ABNM SAM Credit
The American Board of Nuclear Medicine has reviewed and approved this Journal SAM activity submitted by the SNMMI. This activity fulfills the requirements of the ABNM Maintenance of Certification program for self-assessment. 2.0 SAMs have been awarded for this activity.
AMA-PRA (Physician)
The Society for Nuclear Medicine and Medical Imaging, Inc. (SNMMI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. SNMMI designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Objectives
On successful completion of this activity, participants should be able to…
1.The potential complementary role of immune-PET to FDG PET/CT for selecting and monitoring of immune checkpoint inhibitor therapy.
2. The aspects of CD8+ T cell biology that can currently be imaged.
3. How imaging of the tumor microenvironment might be useful in identifying mechanisms of resistance to immune therapies.
Target Audience
This article contains information of value to nuclear medicine physicians and oncologists, as well as to nuclear medicine technologists.
Authors
Amir Iravani1–3 and Rodney J. Hicks1,2
1Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 2Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia; and 3Mallinckrodt Institute of Radiology, School of Medicine, Washington University in St. Louis, Missouri
Disclosure
Professor Hicks is a scientific advisor to and holds shares in Telix Pharmaceuticals, with proceeds donated to his institution. Telix Pharmaceuticals is undertaking a clinical trial using 89Zr-girentuximab, which is mentioned in this review. Professor Hicks is also a member of the Independent Data Management Committee for AAA/Novartis. In accordance with ACCME Revised Standards for Commercial Support and SNMMI Conflict-of-Interest Policy, the authors have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. Disclosure of a relationship is not intended to suggest or to condone bias but is made to provide participants with information that might be of potential importance to their evaluation of the activity.
Contact Information
For questions please contact Lisa Dickinson, Associate Director of Education at ldickinson@snmmi.org or 703-652-6783.
JNM, November 2020, Volume 61, Number 11
Release Date: November 1, 2020
Expiration Date: November 30, 2023
SNMMI Members: Free
Non-Members: $69.00
Continuing Education Credit Information
ABNM SAM Credit
The American Board of Nuclear Medicine has reviewed and approved this Journal SAM activity submitted by the SNMMI. This activity fulfills the requirements of the ABNM Maintenance of Certification program for self-assessment. 2.0 SAMs have been awarded for this activity.
AMA-PRA (Physician)
The Society for Nuclear Medicine and Medical Imaging, Inc. (SNMMI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. SNMMI designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Objectives
On successful completion of this activity, participants should be able to…
1.The potential complementary role of immune-PET to FDG PET/CT for selecting and monitoring of immune checkpoint inhibitor therapy.
2. The aspects of CD8+ T cell biology that can currently be imaged.
3. How imaging of the tumor microenvironment might be useful in identifying mechanisms of resistance to immune therapies.
Target Audience
This article contains information of value to nuclear medicine physicians and oncologists, as well as to nuclear medicine technologists.
Authors
Amir Iravani1–3 and Rodney J. Hicks1,2
1Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 2Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia; and 3Mallinckrodt Institute of Radiology, School of Medicine, Washington University in St. Louis, Missouri
Disclosure
Professor Hicks is a scientific advisor to and holds shares in Telix Pharmaceuticals, with proceeds donated to his institution. Telix Pharmaceuticals is undertaking a clinical trial using 89Zr-girentuximab, which is mentioned in this review. Professor Hicks is also a member of the Independent Data Management Committee for AAA/Novartis. In accordance with ACCME Revised Standards for Commercial Support and SNMMI Conflict-of-Interest Policy, the authors have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. Disclosure of a relationship is not intended to suggest or to condone bias but is made to provide participants with information that might be of potential importance to their evaluation of the activity.
Contact Information
For questions please contact Lisa Dickinson, Associate Director of Education at ldickinson@snmmi.org or 703-652-6783.
